Shengyu Wang
Impact in
- Cancer Research top 10%
- Cancer-related molecular mechanisms research
Papers in
-
- Cancer, Hypoxia, and Metabolism 9
-
- Chronic Obstructive Pulmonary Disease (COPD) Research 10
- Respiratory Support and Mechanisms 6
- Co-authors
- Xin DiaoJing ZhouYang YaoJianghua YanFanghong LuoXin SunXian LinMin Shao
- Journals
- PLoS ONE (4 papers)Medicine (3 papers)Optics Express (2 papers)Journal of Biomedical Nanotechnology (2 papers)Anti-Cancer Drugs (2 papers)
- Partner nations
- ChinaUnited StatesTaiwan
In The Last Decade
Shengyu Wang
131 papers receiving 1.7k citations
Peers
Comparison fields: 5 of 137
- Cancer Research 238
- Critical Care and Intensive Care Medicine 62
- Molecular Biology 685
- Pulmonary and Respiratory Medicine 317
- Immunology 202
Countries citing papers authored by Shengyu Wang
This map shows the geographic impact of Shengyu Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shengyu Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shengyu Wang more than expected).
Fields of papers citing papers by Shengyu Wang
This network shows the impact of papers produced by Shengyu Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shengyu Wang. The network helps show where Shengyu Wang may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Shengyu Wang, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2026 | 0 | |
| 2 | 2025 | 1 | |
| 3 | 2024 | 2 | |
| 4 | 2024 | 4 | |
| 5 | 2024 | 4 | |
| 6 | 2024 | 4 | |
| 7 | 2024 | 1 | |
| 8 | 2024 | 11 | |
| 9 | 2024 | 1 | |
| 10 | 2023 | 8 | |
| 11 | 2023 | 8 | |
| 12 | 2021 | 19 | |
| 13 | 2021 | 2 | |
| 14 | 2019 | 1 | |
| 15 | 2017 | 39 | |
| 16 | 2016 | 6 | |
| 17 | 2014 | 31 | |
| 18 | 2013 | 22 | |
| 19 | 2012 | 3 | |
| 20 | 2011 | 10 |
About Shengyu Wang
Shengyu Wang is a scholar working on Cancer Research, Pulmonary and Respiratory Medicine, Immunology, Oncology and Cellular and Molecular Neuroscience, having authored 141 papers that have together received 1.7k indexed citations. Recurring topics across this work include Angiogenesis and VEGF in Cancer (13 papers), Chronic Obstructive Pulmonary Disease (COPD) Research (10 papers), Asthma and respiratory diseases (10 papers), Axon Guidance and Neuronal Signaling (9 papers), Cancer, Hypoxia, and Metabolism (9 papers), interferon and immune responses (6 papers), Respiratory Support and Mechanisms (6 papers) and Nanoplatforms for cancer theranostics (6 papers). The work is most often cited by research in Cancer Research (238 citations), Critical Care and Intensive Care Medicine (62 citations), Molecular Biology (685 citations), Pulmonary and Respiratory Medicine (317 citations) and Immunology (202 citations). Shengyu Wang has collaborated with scholars based in China, United States and Taiwan. Frequent co-authors include Xin Diao, Jing Zhou, Yang Yao, Jianghua Yan, Fanghong Luo, Xin Sun, Xian Lin, Min Shao, Meilin Jin and Lianzhong Zhao. Their work appears in journals such as PLoS ONE, Medicine, Optics Express, Journal of Biomedical Nanotechnology and Anti-Cancer Drugs.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.